Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Review

Remote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulceration

Authors: J. A. Epps, N. A. Smart

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

An emerging treatment modality for reducing damage caused by ischaemia–reperfusion injury is ischaemic conditioning. This technique induces short periods of ischaemia that have been found to protect against a more significant ischaemic insult. Remote ischaemic conditioning (RIC) can be administered more conveniently and safely, by inflation of a pneumatic blood pressure cuff to a suprasystolic pressure on a limb. Protection is then transferred to a remote organ via humoral and neural pathways. The diabetic state is particularly vulnerable to ischaemia–reperfusion injury, and ischaemia is a significant cause of many diabetic complications, including the diabetic foot. Despite this, studies utilising ischaemic conditioning and RIC in type 2 diabetes have often been disappointing. A newer strategy, repeat RIC, involves the repeated application of short periods of limb ischaemia over days or weeks. It has been demonstrated that this improves endothelial function, skin microcirculation, and modulates the systemic inflammatory response. Repeat RIC was recently shown to be beneficial for healing in lower extremity diabetic ulcers. This article summarises the mechanisms of RIC, and the impact that type 2 diabetes may have upon these, with the role of neural mechanisms in the context of diabetic neuropathy a focus. Repeat RIC may show more promise than RIC in type 2 diabetes, and its potential mechanisms and applications will also be explored. Considering the high costs, rates of chronicity and serious complications resulting from diabetic lower extremity ulceration, repeat RIC has the potential to be an effective novel advanced therapy for this condition.
Literature
1.
go back to reference Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2013;37(3):651–8.PubMedCrossRef Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2013;37(3):651–8.PubMedCrossRef
3.
go back to reference Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–24.PubMedCrossRef Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–24.PubMedCrossRef
4.
go back to reference Tennvall GR, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis. 2004;39(Suppl 2):132–9.CrossRef Tennvall GR, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis. 2004;39(Suppl 2):132–9.CrossRef
5.
go back to reference Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–5.PubMedCrossRef Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–5.PubMedCrossRef
6.
go back to reference Ezzati M. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30.CrossRef Ezzati M. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30.CrossRef
7.
go back to reference Eliasson M, Talbäck M, Rosén M. Improved survival in both men and women with diabetes between 1980 and 2004—a cohort study in Sweden. Cardiovasc Diabetol. 2008;7:32.PubMedPubMedCentralCrossRef Eliasson M, Talbäck M, Rosén M. Improved survival in both men and women with diabetes between 1980 and 2004—a cohort study in Sweden. Cardiovasc Diabetol. 2008;7:32.PubMedPubMedCentralCrossRef
8.
go back to reference Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4(6):537–47.PubMedCrossRef Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4(6):537–47.PubMedCrossRef
9.
go back to reference Crawford F, Cezard G, Chappell FM, Murray GD, Price JF, Sheikh A, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015;19(57):1–207.PubMedPubMedCentralCrossRef Crawford F, Cezard G, Chappell FM, Murray GD, Price JF, Sheikh A, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015;19(57):1–207.PubMedPubMedCentralCrossRef
10.
go back to reference Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491–4.PubMedCrossRef Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491–4.PubMedCrossRef
11.
go back to reference Brownrigg JR, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):128–35.PubMedCrossRef Brownrigg JR, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):128–35.PubMedCrossRef
13.
go back to reference Norman PE, Schoen DE, Gurr JM, Kolybaba ML. High rates of amputation among Indigenous people in Western Australia. Med J Aust. 2010;192(7):421.PubMed Norman PE, Schoen DE, Gurr JM, Kolybaba ML. High rates of amputation among Indigenous people in Western Australia. Med J Aust. 2010;192(7):421.PubMed
14.
go back to reference Venermo M, Manderbacka K, Ikonen T, Keskimäki I, Winel K, Sund R. Amputations and socioeconomic position among persons with diabetes mellitus, a population-based register study. BMJ Open. 2013. doi:10.1136/bmjopen-2012-002395. Venermo M, Manderbacka K, Ikonen T, Keskimäki I, Winel K, Sund R. Amputations and socioeconomic position among persons with diabetes mellitus, a population-based register study. BMJ Open. 2013. doi:10.​1136/​bmjopen-2012-002395.
15.
go back to reference Skrepnek GH, Mills JL, Armstrong DG. A diabetic emergency one million feet long: Disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006–2010. PLoS One. 2015. doi:10.1371/journal.pone.0134914. Skrepnek GH, Mills JL, Armstrong DG. A diabetic emergency one million feet long: Disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006–2010. PLoS One. 2015. doi:10.​1371/​journal.​pone.​0134914.
16.
go back to reference Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle diabetes study. Cardiovasc Diabetol. 2015;14:152.PubMedPubMedCentralCrossRef Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle diabetes study. Cardiovasc Diabetol. 2015;14:152.PubMedPubMedCentralCrossRef
17.
go back to reference Bergin SM, Alford JB, Allard BP, Gurr JM, Holland EL, Horsley MW, et al. A limb lost every 3 hours: can Australia reduce amputations in people with diabetes? Med J Aust. 2012;197(4):197–8.PubMedCrossRef Bergin SM, Alford JB, Allard BP, Gurr JM, Holland EL, Horsley MW, et al. A limb lost every 3 hours: can Australia reduce amputations in people with diabetes? Med J Aust. 2012;197(4):197–8.PubMedCrossRef
18.
go back to reference Lazzarini PA, Gurr JM, Rogers JR, Schox A, Bergin SM. Diabetes foot disease: the Cinderella of Australian diabetes management? J Foot Ankle Res. 2012;5(1):24.PubMedPubMedCentralCrossRef Lazzarini PA, Gurr JM, Rogers JR, Schox A, Bergin SM. Diabetes foot disease: the Cinderella of Australian diabetes management? J Foot Ankle Res. 2012;5(1):24.PubMedPubMedCentralCrossRef
19.
go back to reference Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66(9):1655–62.PubMed Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66(9):1655–62.PubMed
20.
go back to reference Henshaw FR, Boughton P, Lo L, McLennan SV, Twigg SM. Topically applied connective tissue growth factor/CCN2 improves diabetic preclinical cutaneous wound healing: Potential role for CTGF in human diabetic foot ulcer healing. J Diabetes Res. 2015. doi:10.1155/2015/236238. Henshaw FR, Boughton P, Lo L, McLennan SV, Twigg SM. Topically applied connective tissue growth factor/CCN2 improves diabetic preclinical cutaneous wound healing: Potential role for CTGF in human diabetic foot ulcer healing. J Diabetes Res. 2015. doi:10.​1155/​2015/​236238.
21.
go back to reference Noor S, Zubair M, Ahmad J. Diabetic foot ulcer—a review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr. 2015;9(3):192–9.PubMedCrossRef Noor S, Zubair M, Ahmad J. Diabetic foot ulcer—a review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr. 2015;9(3):192–9.PubMedCrossRef
22.
go back to reference Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817–36.PubMedCrossRef Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817–36.PubMedCrossRef
23.
go back to reference Mangialardi G, Madeddu P. Bone marrow-derived stem cells: a mixed blessing in the multifaceted world of diabetic complications. Curr Diab Rep. 2016;16:43.PubMedPubMedCentralCrossRef Mangialardi G, Madeddu P. Bone marrow-derived stem cells: a mixed blessing in the multifaceted world of diabetic complications. Curr Diab Rep. 2016;16:43.PubMedPubMedCentralCrossRef
24.
25.
go back to reference Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014;14(11):1–9.CrossRef Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014;14(11):1–9.CrossRef
26.
go back to reference Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007;117(5):1249–59.PubMedPubMedCentralCrossRef Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007;117(5):1249–59.PubMedPubMedCentralCrossRef
27.
go back to reference Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA. 2009;106(32):13505–10.PubMedPubMedCentralCrossRef Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA. 2009;106(32):13505–10.PubMedPubMedCentralCrossRef
28.
go back to reference Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995;270(21):12607–13.PubMedCrossRef Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995;270(21):12607–13.PubMedCrossRef
29.
go back to reference Boulton AJM, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment. Diabetes Care. 2008;31(8):1679–85.PubMedPubMedCentralCrossRef Boulton AJM, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment. Diabetes Care. 2008;31(8):1679–85.PubMedPubMedCentralCrossRef
30.
go back to reference Mulder G, Tenenhaus M, D’Souza GF. Reduction of diabetic foot ulcer healing times through use of advanced treatment modalities. Int J Lower Extrem Wounds. 2014;13(4):335–46.CrossRef Mulder G, Tenenhaus M, D’Souza GF. Reduction of diabetic foot ulcer healing times through use of advanced treatment modalities. Int J Lower Extrem Wounds. 2014;13(4):335–46.CrossRef
31.
go back to reference Eldor R, Raz I, Yehuda AB, Boulton AJM. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004;21(11):1161–73.PubMedCrossRef Eldor R, Raz I, Yehuda AB, Boulton AJM. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004;21(11):1161–73.PubMedCrossRef
32.
go back to reference Braun LR, Fisk WA, Lev-Tov H, Kirsner RS, Isseroff RR. Diabetic foot ulcer: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):267–81.PubMedCrossRef Braun LR, Fisk WA, Lev-Tov H, Kirsner RS, Isseroff RR. Diabetic foot ulcer: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):267–81.PubMedCrossRef
33.
go back to reference Amin N, Doupis J. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016;7(7):153–64.PubMedPubMedCentralCrossRef Amin N, Doupis J. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016;7(7):153–64.PubMedPubMedCentralCrossRef
34.
go back to reference Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: Part II. Management. J Am Acad Dermatol. 2014;70(1):21.e1–24.CrossRef Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: Part II. Management. J Am Acad Dermatol. 2014;70(1):21.e1–24.CrossRef
35.
go back to reference Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–36.PubMedCrossRef Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–36.PubMedCrossRef
37.
go back to reference Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circulatory Physiol. 2003;285(254–2):H579–88.CrossRef Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circulatory Physiol. 2003;285(254–2):H579–88.CrossRef
38.
go back to reference Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893–9.PubMedCrossRef Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893–9.PubMedCrossRef
39.
go back to reference Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002;106(23):2881–3.PubMedCrossRef Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002;106(23):2881–3.PubMedCrossRef
41.
go back to reference Moses MA, Addison PD, Neligan PC, Ashrafpour H, Huang N, McAllister SE, et al. Inducing late phase of infarct protection in skeletal muscle by remote preconditioning: Efficacy and mechanism. Am J Physiol Regul Integr Comp Physiol. 2005;289(658–6):R1609–17.PubMedCrossRef Moses MA, Addison PD, Neligan PC, Ashrafpour H, Huang N, McAllister SE, et al. Inducing late phase of infarct protection in skeletal muscle by remote preconditioning: Efficacy and mechanism. Am J Physiol Regul Integr Comp Physiol. 2005;289(658–6):R1609–17.PubMedCrossRef
42.
go back to reference Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol. 2005;46(3):450–6.PubMedCrossRef Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol. 2005;46(3):450–6.PubMedCrossRef
43.
go back to reference Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012;79(18):1853–61.PubMedCrossRef Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012;79(18):1853–61.PubMedCrossRef
44.
go back to reference Shaked G, Czeiger D, AbuArar A, Katz T, Harman-Boehm I, Sebbag G. Intermittent cycles of remote ischemic preconditioning augment diabetic foot ulcer healing. Wound Repair Regen. 2015;23(2):191–6.PubMedCrossRef Shaked G, Czeiger D, AbuArar A, Katz T, Harman-Boehm I, Sebbag G. Intermittent cycles of remote ischemic preconditioning augment diabetic foot ulcer healing. Wound Repair Regen. 2015;23(2):191–6.PubMedCrossRef
45.
go back to reference Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens. 2014;27(7):918–25.PubMedCrossRef Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens. 2014;27(7):918–25.PubMedCrossRef
46.
go back to reference Sharma V, Marsh R, Cunniffe B, Cardinale M, Yellon DM, Davidson SM. From protecting the heart to improving athletic performance—the benefits of local and remote ischaemic preconditioning. Cardiovasc Drugs Ther. 2015;29(6):573–88.PubMedCentralCrossRef Sharma V, Marsh R, Cunniffe B, Cardinale M, Yellon DM, Davidson SM. From protecting the heart to improving athletic performance—the benefits of local and remote ischaemic preconditioning. Cardiovasc Drugs Ther. 2015;29(6):573–88.PubMedCentralCrossRef
47.
go back to reference Pickard JM, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, et al. Remote ischemic conditioning: from experimental observation to clinical application: Report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol. 2015;110(1):1–13.CrossRef Pickard JM, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, et al. Remote ischemic conditioning: from experimental observation to clinical application: Report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol. 2015;110(1):1–13.CrossRef
49.
go back to reference Jonker SJ, Menting TP, Warle MC, Ritskes-Hoitinga M, Wever KE. Preclinical evidence for the efficacy of ischemic postconditioning against renal ischemia-reperfusion injury, a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150863.PubMedPubMedCentralCrossRef Jonker SJ, Menting TP, Warle MC, Ritskes-Hoitinga M, Wever KE. Preclinical evidence for the efficacy of ischemic postconditioning against renal ischemia-reperfusion injury, a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150863.PubMedPubMedCentralCrossRef
50.
go back to reference Hu J, Liu S, Jia P, Xu X, Song N, Zhang T, et al. Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis. Crit Care. 2016;20(1):111.PubMedPubMedCentralCrossRef Hu J, Liu S, Jia P, Xu X, Song N, Zhang T, et al. Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis. Crit Care. 2016;20(1):111.PubMedPubMedCentralCrossRef
51.
go back to reference Candilio L, Malik A, Hausenloy DJ. Protection of organs other than the heart by remote ischemic conditioning. J Cardiovasc Med (Hagerstown). 2013;14(3):193–205.CrossRef Candilio L, Malik A, Hausenloy DJ. Protection of organs other than the heart by remote ischemic conditioning. J Cardiovasc Med (Hagerstown). 2013;14(3):193–205.CrossRef
52.
go back to reference Veighey K, Macallister RJ. Clinical applications of remote ischemic preconditioning. Cardiol Res Pract. 2012;2012:620681.PubMedPubMedCentral Veighey K, Macallister RJ. Clinical applications of remote ischemic preconditioning. Cardiol Res Pract. 2012;2012:620681.PubMedPubMedCentral
53.
go back to reference Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol. 2003;285(4):H1435–43.PubMedCrossRef Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol. 2003;285(4):H1435–43.PubMedCrossRef
54.
go back to reference Laude K, Beauchamp P, Thuillez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55(3):466–73.PubMedCrossRef Laude K, Beauchamp P, Thuillez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55(3):466–73.PubMedCrossRef
55.
go back to reference Contractor H, Stottrup NB, Cunnington C, Manlhiot C, Diesch J, Ormerod JO, et al. Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models. Basic Res Cardiol. 2013;108(3):343.PubMedCrossRef Contractor H, Stottrup NB, Cunnington C, Manlhiot C, Diesch J, Ormerod JO, et al. Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models. Basic Res Cardiol. 2013;108(3):343.PubMedCrossRef
56.
go back to reference Epps J, Dieberg G, Smart NA. Repeat remote ischaemic pre-conditioning for improved cardiovascular function in humans: a systematic review. IJC Heart Vasc. 2016;11:55–8.CrossRef Epps J, Dieberg G, Smart NA. Repeat remote ischaemic pre-conditioning for improved cardiovascular function in humans: a systematic review. IJC Heart Vasc. 2016;11:55–8.CrossRef
57.
go back to reference Thijssen DH, Maxwell J, Green DJ, Cable NT, Jones H. Repeated ischaemic preconditioning: A novel therapeutic intervention and potential underlying mechanisms. Exp Physiol. 2016;101(6):677–92. doi:10.1113/EP085566.PubMedCrossRef Thijssen DH, Maxwell J, Green DJ, Cable NT, Jones H. Repeated ischaemic preconditioning: A novel therapeutic intervention and potential underlying mechanisms. Exp Physiol. 2016;101(6):677–92. doi:10.​1113/​EP085566.PubMedCrossRef
58.
go back to reference Madias JE. Sustained blood pressure lowering effect of twice daily remote ischemic conditioning sessions in a normotensive/prehypertensive subject. Int J Cardiol. 2015;182(C):392–4.PubMedCrossRef Madias JE. Sustained blood pressure lowering effect of twice daily remote ischemic conditioning sessions in a normotensive/prehypertensive subject. Int J Cardiol. 2015;182(C):392–4.PubMedCrossRef
60.
go back to reference Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol. 2000;278(5):H1571–6.PubMed Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol. 2000;278(5):H1571–6.PubMed
61.
go back to reference Tang ZL, Dai W, Li YJ, Deng HW. Involvement of capsaicin-sensitive sensory nerves in early and delayed cardioprotection induced by a brief ischaemia of the small intestine. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(3):243–7.PubMedCrossRef Tang ZL, Dai W, Li YJ, Deng HW. Involvement of capsaicin-sensitive sensory nerves in early and delayed cardioprotection induced by a brief ischaemia of the small intestine. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(3):243–7.PubMedCrossRef
62.
go back to reference Aimo A, Borrelli C, Giannoni A, Pastormerlo LE, Barison A, Mirizzi G, et al. Cardioprotection by remote ischemic conditioning: mechanisms and clinical evidences. World J Cardiol. 2015;7(10):621–32.PubMedPubMedCentralCrossRef Aimo A, Borrelli C, Giannoni A, Pastormerlo LE, Barison A, Mirizzi G, et al. Cardioprotection by remote ischemic conditioning: mechanisms and clinical evidences. World J Cardiol. 2015;7(10):621–32.PubMedPubMedCentralCrossRef
63.
go back to reference Wolfrum S, Nienstedt J, Heidbreder M, Schneider K, Dominiak P, Dendorfer A. Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. Regul Pept. 2005;127(1–3):217–24.PubMedCrossRef Wolfrum S, Nienstedt J, Heidbreder M, Schneider K, Dominiak P, Dendorfer A. Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. Regul Pept. 2005;127(1–3):217–24.PubMedCrossRef
64.
go back to reference Jensen RV, Stottrup NB, Kristiansen SB, Botker HE. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol. 2012;107(5):1–9.CrossRef Jensen RV, Stottrup NB, Kristiansen SB, Botker HE. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol. 2012;107(5):1–9.CrossRef
65.
go back to reference Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol. 2010;105(5):651–5.PubMedCrossRef Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol. 2010;105(5):651–5.PubMedCrossRef
66.
go back to reference Gross ER, Hsu AK, Urban TJ, Mochly-Rosen D, Gross GJ. Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C. Basic Res Cardiol. 2013;108(5):381.PubMedCrossRef Gross ER, Hsu AK, Urban TJ, Mochly-Rosen D, Gross GJ. Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C. Basic Res Cardiol. 2013;108(5):381.PubMedCrossRef
67.
go back to reference Donato M, Buchholz B, Rodriguez M, Perez V, Inserte J, Garcia-Dorado D, et al. Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol. 2013;98(2):425–34.PubMedCrossRef Donato M, Buchholz B, Rodriguez M, Perez V, Inserte J, Garcia-Dorado D, et al. Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol. 2013;98(2):425–34.PubMedCrossRef
68.
go back to reference Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, et al. Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones. Cardiovasc Res. 2012;95(4):487–94.PubMedPubMedCentralCrossRef Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, et al. Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones. Cardiovasc Res. 2012;95(4):487–94.PubMedPubMedCentralCrossRef
69.
go back to reference Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol. 2016;111(4):50.PubMedPubMedCentralCrossRef Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol. 2016;111(4):50.PubMedPubMedCentralCrossRef
70.
go back to reference Oba T, Yasukawa H, Nagata T, Kyogoku S, Minami T, Nishihara M, et al. Renal nerve-mediated erythropoietin release confers cardioprotection during remote ischemic preconditioning. Circ J. 2015;79(7):1557–67.PubMedCrossRef Oba T, Yasukawa H, Nagata T, Kyogoku S, Minami T, Nishihara M, et al. Renal nerve-mediated erythropoietin release confers cardioprotection during remote ischemic preconditioning. Circ J. 2015;79(7):1557–67.PubMedCrossRef
71.
go back to reference Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection provided by renal ischemic preconditioning in anesthetized rabbits. Acta Physiol Sin. 2001;53(1):7–12. Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection provided by renal ischemic preconditioning in anesthetized rabbits. Acta Physiol Sin. 2001;53(1):7–12.
72.
go back to reference Mastitskaya S, Basalay M, Hosford PS, Ramage AG, Gourine A, Gourine AV. Identifying the source of a humoral factor of remote (pre)conditioning cardioprotection. PLoS One. 2016;11(2):e0150108.PubMedPubMedCentralCrossRef Mastitskaya S, Basalay M, Hosford PS, Ramage AG, Gourine A, Gourine AV. Identifying the source of a humoral factor of remote (pre)conditioning cardioprotection. PLoS One. 2016;11(2):e0150108.PubMedPubMedCentralCrossRef
73.
go back to reference Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjoquist PO, et al. Remote ischaemic pre- and delayed postconditioning—similar degree of cardioprotection but distinct mechanisms. Exp Physiol. 2012;97(8):908–17.PubMedPubMedCentralCrossRef Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjoquist PO, et al. Remote ischaemic pre- and delayed postconditioning—similar degree of cardioprotection but distinct mechanisms. Exp Physiol. 2012;97(8):908–17.PubMedPubMedCentralCrossRef
74.
go back to reference Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond). 2009;117(5):191–200.PubMedCrossRef Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond). 2009;117(5):191–200.PubMedCrossRef
75.
go back to reference Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674–99.PubMedCrossRef Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674–99.PubMedCrossRef
76.
go back to reference Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Lamon D, et al. Apolipoprotein A-I is a potential mediator of remote ischemic preconditioning. PLoS One. 2013;8(10):e77211.PubMedPubMedCentralCrossRef Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Lamon D, et al. Apolipoprotein A-I is a potential mediator of remote ischemic preconditioning. PLoS One. 2013;8(10):e77211.PubMedPubMedCentralCrossRef
77.
go back to reference Kalakech H, Hibert P, Prunier-Mirebeau D, Tamareille S, Letournel F, Macchi L, et al. RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection. PLoS One. 2014;9(9):e107950.PubMedPubMedCentralCrossRef Kalakech H, Hibert P, Prunier-Mirebeau D, Tamareille S, Letournel F, Macchi L, et al. RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection. PLoS One. 2014;9(9):e107950.PubMedPubMedCentralCrossRef
78.
go back to reference Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, et al. EGLN1 inhibition and rerouting of α-ketoglutarate suffice for remote ischemic protection. Cell. 2016;164(5):884–95.PubMedCrossRef Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, et al. EGLN1 inhibition and rerouting of α-ketoglutarate suffice for remote ischemic protection. Cell. 2016;164(5):884–95.PubMedCrossRef
79.
go back to reference Giricz Z, Varga ZV, Baranyai T, Sipos P, Pálóczi K, Kittel Á, et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol. 2014;68:75–8.PubMedCrossRef Giricz Z, Varga ZV, Baranyai T, Sipos P, Pálóczi K, Kittel Á, et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol. 2014;68:75–8.PubMedCrossRef
80.
go back to reference Hausenloy DJ, Yellon DM. The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther. 2010;24(3):235–54.PubMedCrossRef Hausenloy DJ, Yellon DM. The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther. 2010;24(3):235–54.PubMedCrossRef
82.
go back to reference Kamota T, Li T-S, Morikage N, Murakami M, Ohshima M, Kubo M, et al. Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol. 2009;53(19):1814–22.PubMedCrossRef Kamota T, Li T-S, Morikage N, Murakami M, Ohshima M, Kubo M, et al. Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol. 2009;53(19):1814–22.PubMedCrossRef
83.
go back to reference Czeiger D, Dukhno O, Douvdevani A, Porat Y, Shimoni D, Fulga V, et al. Transient extremity ischemia augments CD34+ progenitor cell availability. Stem Cell Rev. 2011;7(3):639–45.PubMedCrossRef Czeiger D, Dukhno O, Douvdevani A, Porat Y, Shimoni D, Fulga V, et al. Transient extremity ischemia augments CD34+ progenitor cell availability. Stem Cell Rev. 2011;7(3):639–45.PubMedCrossRef
84.
go back to reference Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, Cherepanov V, et al. The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. Physiol Genomics. 2004;19(1):143–50.PubMedCrossRef Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, Cherepanov V, et al. The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. Physiol Genomics. 2004;19(1):143–50.PubMedCrossRef
85.
go back to reference Shimizu M, Saxena P, Konstantinov IE, Cherepanov V, Cheung MM, Wearden P, et al. Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res. 2010;158(1):155–61.PubMedCrossRef Shimizu M, Saxena P, Konstantinov IE, Cherepanov V, Cheung MM, Wearden P, et al. Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res. 2010;158(1):155–61.PubMedCrossRef
86.
go back to reference Cai ZP, Parajuli N, Zheng X, Becker L. Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. Basic Res Cardiol. 2012. doi:10.1007/s00395-012-0277-1. Cai ZP, Parajuli N, Zheng X, Becker L. Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. Basic Res Cardiol. 2012. doi:10.​1007/​s00395-012-0277-1.
87.
go back to reference Hess DC, Blauenfeldt RA, Andersen G, Hougaard KD, Hoda MN, Ding Y, et al. Remote ischaemic conditioning-a new paradigm of self-protection in the brain. Nat Rev Neurol. 2015;11(12):698–710.PubMedCrossRef Hess DC, Blauenfeldt RA, Andersen G, Hougaard KD, Hoda MN, Ding Y, et al. Remote ischaemic conditioning-a new paradigm of self-protection in the brain. Nat Rev Neurol. 2015;11(12):698–710.PubMedCrossRef
89.
go back to reference Zarbock A, Kellum JA. Remote ischemic preconditioning and protection of the kidney-a novel therapeutic option. Crit Care Med. 2016;44(3):607–16.PubMedCrossRef Zarbock A, Kellum JA. Remote ischemic preconditioning and protection of the kidney-a novel therapeutic option. Crit Care Med. 2016;44(3):607–16.PubMedCrossRef
90.
go back to reference Jones WK, Fan GC, Liao S, Zhang JM, Wang Y, Weintraub NL, et al. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation. 2009;120(11 Suppl):S1–9.PubMedPubMedCentralCrossRef Jones WK, Fan GC, Liao S, Zhang JM, Wang Y, Weintraub NL, et al. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation. 2009;120(11 Suppl):S1–9.PubMedPubMedCentralCrossRef
91.
go back to reference Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K. Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome p450 epoxygenase pathway in canine hearts. Cardiovasc Drugs Ther. 2011;25(6):517–22.PubMedPubMedCentralCrossRef Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K. Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome p450 epoxygenase pathway in canine hearts. Cardiovasc Drugs Ther. 2011;25(6):517–22.PubMedPubMedCentralCrossRef
92.
go back to reference Redington KL, Disenhouse T, Strantzas SC, Gladstone R, Wei C, Tropak MB, et al. Remote cardioprotection by direct peripheral nerve stimulation and topical capsaicin is mediated by circulating humoral factors. Basic Res Cardiol. 2012. doi:10.1007/s00395-011-0241-5. Redington KL, Disenhouse T, Strantzas SC, Gladstone R, Wei C, Tropak MB, et al. Remote cardioprotection by direct peripheral nerve stimulation and topical capsaicin is mediated by circulating humoral factors. Basic Res Cardiol. 2012. doi:10.​1007/​s00395-011-0241-5.
93.
go back to reference Redington KL, Disenhouse T, Li J, Wei C, Dai X, Gladstone R, et al. Electroacupuncture reduces myocardial infarct size and improves post-ischemic recovery by invoking release of humoral, dialyzable, cardioprotective factors. J Physiol Sci. 2013;63(3):219–23.PubMedCrossRef Redington KL, Disenhouse T, Li J, Wei C, Dai X, Gladstone R, et al. Electroacupuncture reduces myocardial infarct size and improves post-ischemic recovery by invoking release of humoral, dialyzable, cardioprotective factors. J Physiol Sci. 2013;63(3):219–23.PubMedCrossRef
94.
go back to reference White A, Ernst E. A brief history of acupuncture. Rheumatology (Oxford). 2004;43(5):662–3.CrossRef White A, Ernst E. A brief history of acupuncture. Rheumatology (Oxford). 2004;43(5):662–3.CrossRef
95.
go back to reference Bell RM, Bøtker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, et al. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. 2016;111(4):1–13.CrossRef Bell RM, Bøtker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, et al. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. 2016;111(4):1–13.CrossRef
96.
go back to reference Le Page S, Bejan-Angoulvant T, Angoulvant D, Prunier F. Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol. 2015;110(2):11.PubMedCrossRef Le Page S, Bejan-Angoulvant T, Angoulvant D, Prunier F. Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol. 2015;110(2):11.PubMedCrossRef
97.
go back to reference King N, Dieberg G, Smart NA. Remote ischaemic pre-conditioning does not affect clinical outcomes following coronary artery bypass grafting A systematic review and meta-analysis. Clin Trials Regul Sci Cardiol. 2016;17:1–8.CrossRef King N, Dieberg G, Smart NA. Remote ischaemic pre-conditioning does not affect clinical outcomes following coronary artery bypass grafting A systematic review and meta-analysis. Clin Trials Regul Sci Cardiol. 2016;17:1–8.CrossRef
98.
go back to reference Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142–74.PubMedCrossRef Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142–74.PubMedCrossRef
99.
go back to reference Sardar P, Chatterjee S, Kundu A, Samady H, Owan T, Giri J, et al. Remote ischemic preconditioning in patients undergoing cardiovascular surgery: evidence from a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;221:34–41.PubMedCrossRef Sardar P, Chatterjee S, Kundu A, Samady H, Owan T, Giri J, et al. Remote ischemic preconditioning in patients undergoing cardiovascular surgery: evidence from a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;221:34–41.PubMedCrossRef
100.
go back to reference McCafferty K, Forbes S, Thiemermann C, Yaqoob MM. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech. 2014;7(12):1321–33.PubMedPubMedCentralCrossRef McCafferty K, Forbes S, Thiemermann C, Yaqoob MM. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech. 2014;7(12):1321–33.PubMedPubMedCentralCrossRef
101.
go back to reference Iliodromitis EK, Cohen MV, Dagres N, Andreadou I, Kremastinos DT, Downey JM. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015;20(4):357–69.PubMedCrossRef Iliodromitis EK, Cohen MV, Dagres N, Andreadou I, Kremastinos DT, Downey JM. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015;20(4):357–69.PubMedCrossRef
102.
go back to reference Sivaraman V, Yellon DM. Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther. 2014;19(1):83–96.PubMedCrossRef Sivaraman V, Yellon DM. Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther. 2014;19(1):83–96.PubMedCrossRef
103.
go back to reference Fan Y, Yang S, Zhang X, Cao Y, Huang Y. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats. Clin Exp Pharmacol Physiol. 2012;39(11):938–43.PubMedCrossRef Fan Y, Yang S, Zhang X, Cao Y, Huang Y. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats. Clin Exp Pharmacol Physiol. 2012;39(11):938–43.PubMedCrossRef
105.
go back to reference Sardar P, Chatterjee S, Kundu A, Samady H, Owan T, Giri J, et al. Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;221:34–41.PubMedCrossRef Sardar P, Chatterjee S, Kundu A, Samady H, Owan T, Giri J, et al. Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;221:34–41.PubMedCrossRef
106.
go back to reference Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88(2):531–7.PubMedCrossRef Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88(2):531–7.PubMedCrossRef
107.
go back to reference Wider J, Przyklenk K. Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther. 2014;4(5):383–96.PubMedPubMedCentral Wider J, Przyklenk K. Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther. 2014;4(5):383–96.PubMedPubMedCentral
108.
go back to reference Lejay A, Fang F, John R, Van JAD, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11–22.PubMedCrossRef Lejay A, Fang F, John R, Van JAD, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11–22.PubMedCrossRef
109.
go back to reference Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good? Cardiol Res Pract. 2012;2012:845698.PubMedPubMedCentral Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good? Cardiol Res Pract. 2012;2012:845698.PubMedPubMedCentral
110.
go back to reference Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol. 2012;11:67.PubMedPubMedCentralCrossRef Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol. 2012;11:67.PubMedPubMedCentralCrossRef
111.
go back to reference D’Ascenzo F, Moretti C, Omede P, Cerrato E, Cavallero E, Er F, et al. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention. 2014;9(12):1463–71.PubMedCrossRef D’Ascenzo F, Moretti C, Omede P, Cerrato E, Cavallero E, Er F, et al. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention. 2014;9(12):1463–71.PubMedCrossRef
112.
go back to reference Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54(8):2360–4.PubMedCrossRef Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54(8):2360–4.PubMedCrossRef
113.
go back to reference Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the diabetic human myocardium. J Cell Mol Med. 2010;14(6b):1740–6.PubMedCrossRef Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the diabetic human myocardium. J Cell Mol Med. 2010;14(6b):1740–6.PubMedCrossRef
114.
go back to reference Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99(4):694–704.PubMedPubMedCentralCrossRef Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99(4):694–704.PubMedPubMedCentralCrossRef
115.
go back to reference Bouchard JF, Lamontagne D. Protection afforded by preconditioning to the diabetic heart against ischaemic injury. Cardiovasc Res. 1998;37(1):82–90.PubMedCrossRef Bouchard JF, Lamontagne D. Protection afforded by preconditioning to the diabetic heart against ischaemic injury. Cardiovasc Res. 1998;37(1):82–90.PubMedCrossRef
116.
go back to reference Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. 2011;14(5):781–90.PubMedPubMedCentralCrossRef Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. 2011;14(5):781–90.PubMedPubMedCentralCrossRef
117.
go back to reference Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3β. Diabetes. 2007;56(1):127–36.PubMedCrossRef Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3β. Diabetes. 2007;56(1):127–36.PubMedCrossRef
118.
go back to reference Badalzadeh R, Mohammadi M, Yousefi B, Farajnia S, Najafi M, Mohammadi S. Involvement of glycogen synthase kinase-3 beta and oxidation status in the loss of cardioprotection by postconditioning in chronic diabetic male rats. Adv Pharm Bull. 2015;5(3):321–7.PubMedPubMedCentralCrossRef Badalzadeh R, Mohammadi M, Yousefi B, Farajnia S, Najafi M, Mohammadi S. Involvement of glycogen synthase kinase-3 beta and oxidation status in the loss of cardioprotection by postconditioning in chronic diabetic male rats. Adv Pharm Bull. 2015;5(3):321–7.PubMedPubMedCentralCrossRef
119.
go back to reference Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DDY, et al. Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin Endocrinol (Oxf). 2011;74(6):705–13.PubMedPubMedCentralCrossRef Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DDY, et al. Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin Endocrinol (Oxf). 2011;74(6):705–13.PubMedPubMedCentralCrossRef
120.
go back to reference del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002;55(3):642–59.PubMedCrossRef del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002;55(3):642–59.PubMedCrossRef
121.
go back to reference Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001;280(4):H1744–50.PubMed Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001;280(4):H1744–50.PubMed
122.
go back to reference Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006;69(2):450–8.PubMedCrossRef Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006;69(2):450–8.PubMedCrossRef
123.
go back to reference Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2007;292(2):R920–6.PubMedCrossRef Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2007;292(2):R920–6.PubMedCrossRef
124.
go back to reference Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol. 2001;37(3):711–8.PubMedCrossRef Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol. 2001;37(3):711–8.PubMedCrossRef
125.
go back to reference Lu R, Hu CP, Peng J, Deng HW, Li YJ. Role of calcitonin gene-related peptide in ischaemic preconditioning in diabetic rat hearts. Clin Exp Pharmacol Physiol. 2001;28(5–6):392–6.PubMedCrossRef Lu R, Hu CP, Peng J, Deng HW, Li YJ. Role of calcitonin gene-related peptide in ischaemic preconditioning in diabetic rat hearts. Clin Exp Pharmacol Physiol. 2001;28(5–6):392–6.PubMedCrossRef
126.
go back to reference Sotníková R, Nedelčevová J, Navarová J, Nosáĺová V, Drábiková K, Szöcs K, et al. Protection of the vascular endothelium in experimental situations. Interdiscip Toxicol. 2011;4(1):20–6.PubMedPubMedCentralCrossRef Sotníková R, Nedelčevová J, Navarová J, Nosáĺová V, Drábiková K, Szöcs K, et al. Protection of the vascular endothelium in experimental situations. Interdiscip Toxicol. 2011;4(1):20–6.PubMedPubMedCentralCrossRef
127.
go back to reference Badalzadeh R, Mokhtari B, Yavari R. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci. 2015;65(3):201–15.PubMedCrossRef Badalzadeh R, Mokhtari B, Yavari R. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus. J Physiol Sci. 2015;65(3):201–15.PubMedCrossRef
128.
go back to reference Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2011;300(1):H118–24.PubMedCrossRef Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2011;300(1):H118–24.PubMedCrossRef
129.
go back to reference Jensen RV, Zachara NE, Nielsen PH, Kimose HH, Kristiansen SB, Botker HE. Impact of o-GIcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc Res. 2013;97(2):369–78.PubMedCrossRef Jensen RV, Zachara NE, Nielsen PH, Kimose HH, Kristiansen SB, Botker HE. Impact of o-GIcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc Res. 2013;97(2):369–78.PubMedCrossRef
130.
go back to reference Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res. 1997;34(1):113–20.PubMedCrossRef Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res. 1997;34(1):113–20.PubMedCrossRef
131.
go back to reference Ma G, Al-Shabrawey M, Johnson JA, Datar R, Tawfik HE, Guo D, et al. Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):415–27.PubMedCrossRef Ma G, Al-Shabrawey M, Johnson JA, Datar R, Tawfik HE, Guo D, et al. Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):415–27.PubMedCrossRef
132.
go back to reference Ravingerova T, Neckar J, Kolar F. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mol Cell Biochem. 2003;249(1–2):167–74.PubMedCrossRef Ravingerova T, Neckar J, Kolar F. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mol Cell Biochem. 2003;249(1–2):167–74.PubMedCrossRef
133.
go back to reference Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008;45(1):41–6.PubMedCrossRef Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008;45(1):41–6.PubMedCrossRef
134.
go back to reference Baranyai T, Nagy CT, Koncsos G, Onodi Z, Karolyi-Szabo M, Makkos A, et al. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. 2015;14:151.PubMedPubMedCentralCrossRef Baranyai T, Nagy CT, Koncsos G, Onodi Z, Karolyi-Szabo M, Makkos A, et al. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. 2015;14:151.PubMedPubMedCentralCrossRef
135.
go back to reference Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol. 2000;278(4):H1218–24.PubMed Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol. 2000;278(4):H1218–24.PubMed
136.
go back to reference Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 1998;275(2 Pt 2):H721–5.PubMed Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 1998;275(2 Pt 2):H721–5.PubMed
137.
go back to reference Liu M, Zhou B, Xia ZY, Zhao B, Lei SQ, Yang QJ, et al. Hyperglycemia-induced inhibition of DJ-1 expression compromised the effectiveness of ischemic postconditioning cardioprotection in rats. Oxid Med Cell Longev. 2013;2013:564902.PubMedPubMedCentral Liu M, Zhou B, Xia ZY, Zhao B, Lei SQ, Yang QJ, et al. Hyperglycemia-induced inhibition of DJ-1 expression compromised the effectiveness of ischemic postconditioning cardioprotection in rats. Oxid Med Cell Longev. 2013;2013:564902.PubMedPubMedCentral
138.
go back to reference Fullmer TM, Pei S, Zhu Y, Sloan C, Manzanares R, Henrie B, et al. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol. 2013;64:20–9.PubMedCrossRef Fullmer TM, Pei S, Zhu Y, Sloan C, Manzanares R, Henrie B, et al. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol. 2013;64:20–9.PubMedCrossRef
139.
go back to reference Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod JH. Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology. 2011;114(6):1364–72.PubMedCrossRef Drenger B, Ostrovsky IA, Barak M, Nechemia-Arbely Y, Ziv E, Axelrod JH. Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology. 2011;114(6):1364–72.PubMedCrossRef
140.
go back to reference Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia–reperfusion injury in rats. Diabetologia. 2006;49(12):3075–84.PubMedCrossRef Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia–reperfusion injury in rats. Diabetologia. 2006;49(12):3075–84.PubMedCrossRef
141.
go back to reference Dang Z, Maselli D, Spinetti G, Sangalli E, Carnelli F, Rosa F, et al. Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. Diabetologia. 2015;58(11):2653–62.PubMedPubMedCentralCrossRef Dang Z, Maselli D, Spinetti G, Sangalli E, Carnelli F, Rosa F, et al. Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. Diabetologia. 2015;58(11):2653–62.PubMedPubMedCentralCrossRef
142.
go back to reference Fadini GP, Ferraro F, Quaini F, Asahara T, Madeddu P. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med. 2014;3(8):949–57.PubMedPubMedCentralCrossRef Fadini GP, Ferraro F, Quaini F, Asahara T, Madeddu P. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med. 2014;3(8):949–57.PubMedPubMedCentralCrossRef
143.
go back to reference Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: Relevance to impaired endothelial progenitor cells mobilization. PLoS One. 2012. doi:10.1371/journal.pone.0050739. Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: Relevance to impaired endothelial progenitor cells mobilization. PLoS One. 2012. doi:10.​1371/​journal.​pone.​0050739.
144.
go back to reference Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis. 2013;229(1):23–9.PubMedCrossRef Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis. 2013;229(1):23–9.PubMedCrossRef
145.
go back to reference Rana A, Goyal N, Ahlawat A, Jamwal S, Reddy BV, Sharma S. Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders. Perfusion. 2015;30(2):94–105.PubMedCrossRef Rana A, Goyal N, Ahlawat A, Jamwal S, Reddy BV, Sharma S. Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders. Perfusion. 2015;30(2):94–105.PubMedCrossRef
146.
go back to reference Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol. 2010;643(1):78–83.PubMedCrossRef Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol. 2010;643(1):78–83.PubMedCrossRef
147.
go back to reference Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295(4):H1580–6.PubMedPubMedCentralCrossRef Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295(4):H1580–6.PubMedPubMedCentralCrossRef
148.
go back to reference Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C. Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2013;61(1):35–41.PubMedCrossRef Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C. Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2013;61(1):35–41.PubMedCrossRef
149.
go back to reference Buchholz B, Donato M, D’Annunzio V, Gelpi RJ. Ischemic postconditioning: mechanisms, comorbidities, and clinical application. Mol Cell Biochem. 2014;392(1–2):1–12.PubMedCrossRef Buchholz B, Donato M, D’Annunzio V, Gelpi RJ. Ischemic postconditioning: mechanisms, comorbidities, and clinical application. Mol Cell Biochem. 2014;392(1–2):1–12.PubMedCrossRef
150.
go back to reference Helgeland E, Breivik L, Sishi BJ, Engelbrecht AM, Jonassen AK. Intermittent insulin treatment mimics ischemic postconditioning via mitoKATP channels, ROS, and RISK. Scand Cardiovasc J. 2015;49(5):270–9.PubMedCrossRef Helgeland E, Breivik L, Sishi BJ, Engelbrecht AM, Jonassen AK. Intermittent insulin treatment mimics ischemic postconditioning via mitoKATP channels, ROS, and RISK. Scand Cardiovasc J. 2015;49(5):270–9.PubMedCrossRef
151.
go back to reference Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011;106(6):925–52.PubMedCrossRef Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011;106(6):925–52.PubMedCrossRef
152.
go back to reference Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27(1):5–16.PubMedCrossRef Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27(1):5–16.PubMedCrossRef
153.
go back to reference Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008;103(3):274–84.PubMedCrossRef Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008;103(3):274–84.PubMedCrossRef
154.
go back to reference Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491–9.PubMedCrossRef Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491–9.PubMedCrossRef
155.
go back to reference Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol. 2005;42(5–6):219–32.PubMedCrossRef Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol. 2005;42(5–6):219–32.PubMedCrossRef
156.
go back to reference Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115(23):2909–16.PubMedCrossRef Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115(23):2909–16.PubMedCrossRef
157.
go back to reference Gu W, Kehl F, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism. Anesthesiology. 2008;108(4):634–42.PubMedPubMedCentralCrossRef Gu W, Kehl F, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism. Anesthesiology. 2008;108(4):634–42.PubMedPubMedCentralCrossRef
158.
go back to reference Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther. 2013;18(3):263–9.PubMedCrossRef Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther. 2013;18(3):263–9.PubMedCrossRef
159.
go back to reference Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454–65.PubMedCrossRef Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454–65.PubMedCrossRef
160.
go back to reference Hotta H, Miura T, Miki T, Togashi N, Maeda T, Kim SJ, et al. Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res. 2010;106(1):129–32.PubMedCrossRef Hotta H, Miura T, Miki T, Togashi N, Maeda T, Kim SJ, et al. Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res. 2010;106(1):129–32.PubMedCrossRef
161.
go back to reference Kleinbongard P, Neuhauser M, Thielmann M, Kottenberg E, Peters J, Jakob H, et al. Confounders of cardioprotection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting. Cardiology. 2016;133(2):128–33.PubMedCrossRef Kleinbongard P, Neuhauser M, Thielmann M, Kottenberg E, Peters J, Jakob H, et al. Confounders of cardioprotection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting. Cardiology. 2016;133(2):128–33.PubMedCrossRef
162.
go back to reference Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1226–40. Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1226–40.
163.
go back to reference Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur J Intern Med. 2001;12(1):20–7.PubMedCrossRef Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur J Intern Med. 2001;12(1):20–7.PubMedCrossRef
164.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93.PubMedPubMedCentralCrossRef Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93.PubMedPubMedCentralCrossRef
165.
go back to reference Rota E, Quadri R, Fanti E, Isoardo G, Poglio F, Tavella A, et al. Electrophysiological findings of peripheral neuropathy in newly diagnosed type II diabetes mellitus. J Peripher Nerv Syst. 2005;10(4):348–53.PubMedCrossRef Rota E, Quadri R, Fanti E, Isoardo G, Poglio F, Tavella A, et al. Electrophysiological findings of peripheral neuropathy in newly diagnosed type II diabetes mellitus. J Peripher Nerv Syst. 2005;10(4):348–53.PubMedCrossRef
166.
go back to reference Alcayaga-Miranda F, Varas-Godoy M, Khoury M. Harnessing the angiogenic potential of stem cell-derived exosomes for vascular regeneration. Stem Cells Intl. 2016;2016:3409169.CrossRef Alcayaga-Miranda F, Varas-Godoy M, Khoury M. Harnessing the angiogenic potential of stem cell-derived exosomes for vascular regeneration. Stem Cells Intl. 2016;2016:3409169.CrossRef
167.
go back to reference Elsharawy MA, Naim M, Greish S. Human CD34+ stem cells promote healing of diabetic foot ulcers in rats. Interact CardioVasc Thorac Surg. 2012;14(3):288–93.PubMedCrossRef Elsharawy MA, Naim M, Greish S. Human CD34+ stem cells promote healing of diabetic foot ulcers in rats. Interact CardioVasc Thorac Surg. 2012;14(3):288–93.PubMedCrossRef
168.
go back to reference Albiero M, Poncina N, Tjwa M, Ciciliot S, Menegazzo L, Ceolotto G, et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes. 2014;63(4):1353–65.PubMedCrossRef Albiero M, Poncina N, Tjwa M, Ciciliot S, Menegazzo L, Ceolotto G, et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes. 2014;63(4):1353–65.PubMedCrossRef
169.
go back to reference Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med. 2011;3(104):104ral.CrossRef Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med. 2011;3(104):104ral.CrossRef
170.
go back to reference Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med. 2009;206(13):2897–906.PubMedPubMedCentralCrossRef Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med. 2009;206(13):2897–906.PubMedPubMedCentralCrossRef
171.
go back to reference Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407–21.PubMedCrossRef Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407–21.PubMedCrossRef
172.
go back to reference Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne). 2014;5:e205. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne). 2014;5:e205.
174.
175.
go back to reference DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective”. Heart Int. 2014;9(2):37–44.PubMedPubMedCentral DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective”. Heart Int. 2014;9(2):37–44.PubMedPubMedCentral
177.
go back to reference Gatopoulou A, Papanas N, Maltezos E. Diabetic gastrointestinal autonomic neuropathy: current status and new achievements for everyday clinical practice. Eur J Intern Med. 2012;23(6):499–505.PubMedCrossRef Gatopoulou A, Papanas N, Maltezos E. Diabetic gastrointestinal autonomic neuropathy: current status and new achievements for everyday clinical practice. Eur J Intern Med. 2012;23(6):499–505.PubMedCrossRef
178.
go back to reference Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24(7):1264–9.PubMedCrossRef Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24(7):1264–9.PubMedCrossRef
179.
180.
go back to reference Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med. 2002;19(1):65–9.PubMedCrossRef Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med. 2002;19(1):65–9.PubMedCrossRef
181.
go back to reference Juhn MS, Parsons B, Varvara R, Sadosky A. Pregabalin for painful diabetic peripheral neuropathy: strategies for dosing, monotherapy vs. Combination therapy, treatment-refractory patients, and adverse events. Curr Med Res Opin. 2015;31(5):1017–26.PubMedCrossRef Juhn MS, Parsons B, Varvara R, Sadosky A. Pregabalin for painful diabetic peripheral neuropathy: strategies for dosing, monotherapy vs. Combination therapy, treatment-refractory patients, and adverse events. Curr Med Res Opin. 2015;31(5):1017–26.PubMedCrossRef
183.
go back to reference Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105(1–2):133–41.PubMedCrossRef Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105(1–2):133–41.PubMedCrossRef
184.
go back to reference Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–8.PubMedCrossRef Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–8.PubMedCrossRef
185.
go back to reference Li D, Li NS, Chen QQ, Guo R, Xu PS, Deng HW, et al. Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts. Regul Pept. 2008;147(1–3):4–8.PubMedCrossRef Li D, Li NS, Chen QQ, Guo R, Xu PS, Deng HW, et al. Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts. Regul Pept. 2008;147(1–3):4–8.PubMedCrossRef
186.
go back to reference Papanas N, Ziegler D. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine. 2014;47(3):690–8.PubMedCrossRef Papanas N, Ziegler D. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine. 2014;47(3):690–8.PubMedCrossRef
187.
go back to reference Dyck PJ, Herrmann DN, Staff NP, Dyck PJ. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes. 2013;62(11):3677–86.PubMedPubMedCentralCrossRef Dyck PJ, Herrmann DN, Staff NP, Dyck PJ. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes. 2013;62(11):3677–86.PubMedPubMedCentralCrossRef
188.
go back to reference Yamaguchi T, Izumi Y, Nakamura Y, Yamazaki T, Shiota M, Sano S, et al. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol. 2015;178:239–46.PubMedCrossRef Yamaguchi T, Izumi Y, Nakamura Y, Yamazaki T, Shiota M, Sano S, et al. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol. 2015;178:239–46.PubMedCrossRef
189.
go back to reference Liang Y, Li YP, He F, Liu XQ, Zhang JY. Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease. Braz J Med Biol Res. 2015;48(6):568–76.PubMedPubMedCentralCrossRef Liang Y, Li YP, He F, Liu XQ, Zhang JY. Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease. Braz J Med Biol Res. 2015;48(6):568–76.PubMedPubMedCentralCrossRef
190.
go back to reference Karakoyun R, Koksoy C, Yilmaz TU, Altun H, Banli O, Albayrak A, et al. The angiogenic effects of ischemic conditioning in experimental critical limb ischemia. Eur J Vasc Endovasc Surg. 2014;47(2):172–9.PubMedCrossRef Karakoyun R, Koksoy C, Yilmaz TU, Altun H, Banli O, Albayrak A, et al. The angiogenic effects of ischemic conditioning in experimental critical limb ischemia. Eur J Vasc Endovasc Surg. 2014;47(2):172–9.PubMedCrossRef
191.
go back to reference Wei M, Xin P, Li S, Tao J, Li Y, Li J, et al. Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res. 2011;108(10):1220–5.PubMedCrossRef Wei M, Xin P, Li S, Tao J, Li Y, Li J, et al. Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res. 2011;108(10):1220–5.PubMedCrossRef
192.
go back to reference Cherry-Allen KM, Gidday JM, Lee JM, Hershey T, Lang CE. Remote limb ischemic conditioning enhances motor learning in healthy humans. J Neurophysiol. 2015;113(10):3708–19.PubMedPubMedCentralCrossRef Cherry-Allen KM, Gidday JM, Lee JM, Hershey T, Lang CE. Remote limb ischemic conditioning enhances motor learning in healthy humans. J Neurophysiol. 2015;113(10):3708–19.PubMedPubMedCentralCrossRef
193.
go back to reference Meng R, Ding Y, Asmaro K, Brogan D, Meng L, Sui M, et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment. Neurotherapeutics. 2015;12(3):667–77.PubMedPubMedCentralCrossRef Meng R, Ding Y, Asmaro K, Brogan D, Meng L, Sui M, et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment. Neurotherapeutics. 2015;12(3):667–77.PubMedPubMedCentralCrossRef
194.
go back to reference Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, et al. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol. 2010;299(3):H752–62.PubMedPubMedCentralCrossRef Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, et al. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol. 2010;299(3):H752–62.PubMedPubMedCentralCrossRef
195.
go back to reference Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, et al. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation. 2008;118(19):1961–9.PubMedPubMedCentralCrossRef Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, et al. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation. 2008;118(19):1961–9.PubMedPubMedCentralCrossRef
196.
go back to reference Luca MC, Liuni A, McLaughlin K, Gori T, Parker JD. Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: A human study. J Am Heart Assoc. 2013. doi:10.1161/JAHA.112.000075. Luca MC, Liuni A, McLaughlin K, Gori T, Parker JD. Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: A human study. J Am Heart Assoc. 2013. doi:10.​1161/​JAHA.​112.​000075.
197.
go back to reference Kimura M, Ueda K, Goto C, Jitsuiki D, Nishioka K, Umemura T, et al. Repetition of ischemic preconditioning augments endothelium-dependent vasodilation in humans: role of endothelium-derived nitric oxide and endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2007;27(6):1403–10.PubMedCrossRef Kimura M, Ueda K, Goto C, Jitsuiki D, Nishioka K, Umemura T, et al. Repetition of ischemic preconditioning augments endothelium-dependent vasodilation in humans: role of endothelium-derived nitric oxide and endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2007;27(6):1403–10.PubMedCrossRef
198.
go back to reference Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999;68(5):1905–12.PubMedCrossRef Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999;68(5):1905–12.PubMedCrossRef
199.
go back to reference Takizawa S, Nagata E, Nakayama T, Masuda H, Asahara T. Recent progress in endothelial progenitor cell culture systems: potential for stroke therapy. Neurol Med Chir (Tokyo). 2016;56(6):302–9.PubMedPubMedCentralCrossRef Takizawa S, Nagata E, Nakayama T, Masuda H, Asahara T. Recent progress in endothelial progenitor cell culture systems: potential for stroke therapy. Neurol Med Chir (Tokyo). 2016;56(6):302–9.PubMedPubMedCentralCrossRef
200.
go back to reference Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003;23(2):117–45.PubMedCrossRef Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003;23(2):117–45.PubMedCrossRef
201.
go back to reference Thom SR, Hampton M, Troiano MA, Mirza Z, Malay DS, Shannon S, et al. Measurements of CD34+/CD45-dim stem cells predict healing of diabetic neuropathic wounds. Diabetes. 2016;65(2):486–97.PubMedCrossRef Thom SR, Hampton M, Troiano MA, Mirza Z, Malay DS, Shannon S, et al. Measurements of CD34+/CD45-dim stem cells predict healing of diabetic neuropathic wounds. Diabetes. 2016;65(2):486–97.PubMedCrossRef
202.
go back to reference Jeong J-O, Kim M-O, Kim H, Lee M-Y, Kim S-W, Ii M, et al. Dual angiogenic and neurotrophic effects of bone marrow–derived endothelial progenitor cells on diabetic neuropathy. Circulation. 2009;119(5):699–708.PubMedPubMedCentralCrossRef Jeong J-O, Kim M-O, Kim H, Lee M-Y, Kim S-W, Ii M, et al. Dual angiogenic and neurotrophic effects of bone marrow–derived endothelial progenitor cells on diabetic neuropathy. Circulation. 2009;119(5):699–708.PubMedPubMedCentralCrossRef
204.
go back to reference Van Craenenbroeck EM, Conraads VM. Endothelial progenitor cells in vascular health: focus on lifestyle. Microvasc Res. 2010;79(3):184–92.PubMedCrossRef Van Craenenbroeck EM, Conraads VM. Endothelial progenitor cells in vascular health: focus on lifestyle. Microvasc Res. 2010;79(3):184–92.PubMedCrossRef
205.
go back to reference Li TB, Zhang JJ, Liu B, Liu WQ, Wu Y, Xiong XM, et al. Involvement of NADPH oxidases and non-muscle myosin light chain in senescence of endothelial progenitor cells in hyperlipidemia. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(3):289–302.PubMedCrossRef Li TB, Zhang JJ, Liu B, Liu WQ, Wu Y, Xiong XM, et al. Involvement of NADPH oxidases and non-muscle myosin light chain in senescence of endothelial progenitor cells in hyperlipidemia. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(3):289–302.PubMedCrossRef
206.
go back to reference Sloth AD, Schmidt MR, Munk K, Schmidt M, Pedersen L, Sorensen HT, et al. Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial. BMJ Open. 2015;5(4):e006923.PubMedPubMedCentralCrossRef Sloth AD, Schmidt MR, Munk K, Schmidt M, Pedersen L, Sorensen HT, et al. Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial. BMJ Open. 2015;5(4):e006923.PubMedPubMedCentralCrossRef
207.
go back to reference Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.PubMedCrossRef Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.PubMedCrossRef
208.
go back to reference Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol. 2013;12:154.PubMedPubMedCentralCrossRef Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol. 2013;12:154.PubMedPubMedCentralCrossRef
209.
go back to reference Liu Y, Wei J, Hu S, Hu L. Beneficial effects of statins on endothelial progenitor cells. Am J Med Sci. 2012;344(3):220–6.PubMedCrossRef Liu Y, Wei J, Hu S, Hu L. Beneficial effects of statins on endothelial progenitor cells. Am J Med Sci. 2012;344(3):220–6.PubMedCrossRef
210.
go back to reference Hibbert B, Simard T, Ramirez FD, Pourdjabbar A, Raizman JE, Maze R, et al. The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J Cardiovasc Pharmacol. 2013;62(5):491–6.PubMedCrossRef Hibbert B, Simard T, Ramirez FD, Pourdjabbar A, Raizman JE, Maze R, et al. The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J Cardiovasc Pharmacol. 2013;62(5):491–6.PubMedCrossRef
211.
go back to reference Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, De Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1α. Diabetes Care. 2010;33(7):1607–9.PubMedPubMedCentralCrossRef Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, De Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1α. Diabetes Care. 2010;33(7):1607–9.PubMedPubMedCentralCrossRef
212.
go back to reference Delagarde H, Ouadraougo N, Grall S, Macchi L, Roy PM, Abraham P, et al. Remote ischaemic preconditioning in intermittent claudication. Arch Cardiovasc Dis. 2015;108(10):472–9.PubMedCrossRef Delagarde H, Ouadraougo N, Grall S, Macchi L, Roy PM, Abraham P, et al. Remote ischaemic preconditioning in intermittent claudication. Arch Cardiovasc Dis. 2015;108(10):472–9.PubMedCrossRef
213.
go back to reference Whittaker P, Przyklenk K. From ischemic conditioning to ‘hyperconditioning’: clinical phenomenon and basic science opportunity. Dose-Response. 2014;12(4):650–63.PubMedPubMedCentralCrossRef Whittaker P, Przyklenk K. From ischemic conditioning to ‘hyperconditioning’: clinical phenomenon and basic science opportunity. Dose-Response. 2014;12(4):650–63.PubMedPubMedCentralCrossRef
214.
go back to reference Heyman SN, Leibowitz D, Mor-Yosef Levi I, Liberman A, Eisenkraft A, Elcalai R, et al. Adaptive response to hypoxia and remote ischemia preconditioning: a new HIF era in clinical medicine. Acta Physiol (Oxf). 2015. doi:10.1111/apha.12613.PubMed Heyman SN, Leibowitz D, Mor-Yosef Levi I, Liberman A, Eisenkraft A, Elcalai R, et al. Adaptive response to hypoxia and remote ischemia preconditioning: a new HIF era in clinical medicine. Acta Physiol (Oxf). 2015. doi:10.​1111/​apha.​12613.PubMed
215.
go back to reference Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–86.PubMedCrossRef Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–86.PubMedCrossRef
216.
go back to reference Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137–48.PubMedCrossRef Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137–48.PubMedCrossRef
217.
go back to reference Fadini GP, Avogaro A. It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. Exp Diabetes Res. 2012;2012:742976.PubMedPubMedCentral Fadini GP, Avogaro A. It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. Exp Diabetes Res. 2012;2012:742976.PubMedPubMedCentral
Metadata
Title
Remote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulceration
Authors
J. A. Epps
N. A. Smart
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0444-z

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue